Harm Reduction Therp Drug Patent Portfolio
Harm Reduction Therp owns 1 orange book drug protected by 2 US patents Given below is the list of Harm Reduction Therp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020343 | Intranasal pharmaceutical dosage forms comprising naloxone | 11 May, 2032 | Active |
| US11806428 | Intranasal pharmaceutical dosage forms comprising naloxone | 11 May, 2032 | Active |
Latest Legal Activities on Harm Reduction Therp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Harm Reduction Therp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11806428 |
|
Email Notification
Critical
| 07 Nov, 2023 | US11806428 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Nov, 2023 | US11806428 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11806428 |
| Patent eGrant Notification | 07 Nov, 2023 | US11806428 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Nov, 2023 | US11806428 |
|
Email Notification
Critical
| 19 Oct, 2023 | US11806428 |
|
Issue Notification Mailed
Critical
| 18 Oct, 2023 | US11806428 |
|
Application Is Considered Ready for Issue
Critical
| 04 Oct, 2023 | US11806428 |
| Dispatch to FDC | 04 Oct, 2023 | US11806428 |
| Printer Rush- No mailing | 22 Sep, 2023 | US11806428 |
|
Pubs Case Remand to TC
Critical
| 21 Sep, 2023 | US11806428 |
|
Issue Fee Payment Received
Critical
| 20 Sep, 2023 | US11806428 |
|
Issue Fee Payment Verified
Critical
| 20 Sep, 2023 | US11806428 |
|
Mail Notice of Allowance
Critical
| 19 Sep, 2023 | US11806428 |
Harm Reduction Therp's Family Patents
Harm Reduction Therp Drug List
Given below is the complete list of Harm Reduction Therp's drugs and the patents protecting them.
1. Rivive
Rivive is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020343 | Intranasal pharmaceutical dosage forms comprising naloxone |
11 May, 2032
(7 years from now)
| Active |
| US11806428 | Intranasal pharmaceutical dosage forms comprising naloxone |
11 May, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rivive's drug page